Synthetic Biologics Announces Recent International Patents that Bolster its C. difficile Program

[PR Newswire] – ROCKVILLE, Md., May 8, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced tod more

View todays social media effects on SYN

View the latest stocks trending across Twitter. Click to view dashboard

See who Synthetic is hiring next, click here to view